NDAINJECTIONINJECTABLE
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug Shortage Active
RIFADIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
RIFADIN (rifampin) by Sanofi. Approved for rifamycin antibacterial [epc]. First approved in 1989.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFADIN (rifampin) is a rifamycin-class antibacterial small molecule administered by injection, approved in 1989. It is used to treat serious bacterial infections, particularly tuberculosis and other mycobacterial diseases. Rifampin works by inhibiting bacterial RNA polymerase, disrupting transcription in susceptible organisms.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30% rating), brand team size and commercial investment are likely modest.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
Started Sep 2026
14 enrolled
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
Started May 2026
28 enrolled
Healthy Volunteers (HV)
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Started Apr 2026
280 enrolled
Rifampin-resistant TuberculosisDrug-resistant Tuberculosis
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
Started Mar 2026
28 enrolled
Clinical Pharmacology
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Started Dec 2025
22 enrolled
Healthy Volunteers
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.